Tests IKS03 drug in adults with advanced B-cell non-Hodgkin lymphoma
Tests the safety of IKS03, a CD19-targeting drug, in adults with advanced B-cell lymphoma.
Key facts
- Who runs it
- Iksuda Therapeutics Ltd.
- Where
- Baltimore, United StatesSee the siteAlso in 4 other countries, 12 sites
- Trial code
- Registry title
- IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 140 people, planned
- Started
- 5 Sept 2023
- Expected to end
- Sept 2028
- Type of study
- Interventional, 5 groups
- Treatments tested
- IKS03
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced B cell non-Hodgkin lymphoma that came back or did not respond to earlier treatment, to test a new drug called IKS03.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Advanced B cell non-Hodgkin lymphoma that came back, did not respond to treatment, or has no standard treatment. Part I excludes Burkitt lymphoma, Waldenström macroglobulinemia and chronic lymphocytic leukemia. In Part II the lymphoma must be measurable. Possible groups include diffuse large B cell, follicular and mantle cell lymphoma.
- Earlier treatment
- Must have had at least 2 earlier lines of systemic treatment. Must need systemic treatment and not need immediate treatment to shrink the tumor. Cannot join with any CD19-targeted therapy within 4 weeks, or another investigational treatment within 3 weeks.
- Biomarker or test result
- The lymphoma must be CD19-positive (Part II requires it; Part I asks for it if feasible). People with CD19-negative lymphoma cannot join.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Lymphoma in the brain or spinal fluid not controlled by earlier surgery or radiotherapy
- Known HIV infection or AIDS
- Active hepatitis B or hepatitis C infection
- Serious heart, liver, lung or eye disease, or earlier solid organ transplant
The registry criteria, word for word
Show all 49 criteriaShow less
Who can take part
- Males or females, ≥ 18 years of age
- Part I: documented B cell NHL (any subtype except Burkitt lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia); previously confirmed CD19-positive if feasible
- Part II: documented B cell NHL (subtypes to be determined); confirmed CD19-positive; possible expansion cohorts may include:; Diffuse large B cell lymphoma (including germinal center B cell type, activated B cell type); Follicular lymphoma (including duodenal-type follicular lymphoma); Mantle cell lymphoma; B cell lymphomas not specified
- If B cell NHL subtype likely to have bone marrow involvement must be willing to undergo bone marrow biopsy in the event of an on-study complete response to confirm response
- NHL that is relapsed, refractory to, or intolerant of existing therapy(ies) with known curative potential, or for which no standard therapy is available; must have received at least 2 prior lines of systemic therapy
- Must be in need of systemic treatment and not require immediate cytoreductive therapy
- Part I: measurable or non-measurable disease
- Part II: measurable disease according to The Revised Criteria/Lugano Classification
- Part I: screening tumor biopsy requested, but optional; Part 2: patient must agree to screening tumor biopsy
- ECOG performance status 0 or 1
- Women of childbearing potential and fertile men agreeing to use two effective methods of contraception (including a highly effective method of contraception); women beginning 2 weeks prior to the first dose, men beginning prior to the first dose, and both continuing until 8 months after the last dose of study drug; male patients must also agree to refrain from sperm donation during this period
- Ability to understand and give written informed consent
Who cannot take part
- Women who are pregnant or intending to become pregnant before, during, or within 8 months after the last dose of study drug; women who are breastfeeding
- Central nervous system (CNS) lymphoma, leptomeningeal infiltration, or spinal cord compression not controlled by prior surgery or radiotherapy; symptoms suggesting CNS involvement
- Inadequate recovery from a surgical procedure, or a major surgical procedure within 4 weeks
- Receipt of:; Any CD19-targeted therapy within 4 weeks; Any tumor vaccine within 6 weeks (must have progressed if previously received)
- Prior autologous/allogeneic CAR-T therapy if known to be CD19-negative after
- Drugs known to impair renal function, including:; NSAIDS within 3 days; Aminoglycoside antibiotics, amphotericin B, etc. within 1 week; Bisphosphonates within 1 month
- Prior solid organ transplant
- Allogeneic HSCT within 6 months, or:; If receiving immunosuppression; If with active evidence of GVHD
- Autologous hematopoietic stem cell transplantation (HSCT) within 3 months
- Radiotherapy:; To target lesions within 4 weeks unless progression of the lesion has been documented; To non-target lesions within 1 week
- Immunosuppressive or systemic glucocorticoid therapy (> 10 mg prednisone daily or equivalent) within 2 weeks
- Herbal therapies and supplements within 2 weeks
- Strong inhibitors of cytochrome P450 within 2 weeks
- Part 2: History of another malignancy within 2 years, with the exception of:; Treated, non-melanoma skin cancers; Treated carcinoma in situ (e.g., breast, cervix); Controlled, superficial carcinoma of the urinary bladder; T1a or b prostate carcinoma treated according to standard of care, with PSA within normal limits; Papillary thyroid carcinoma Stage I treated surgically for cure
- Patients with:; Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks unless adequately treated and stable; Active uncontrolled bleeding or a known bleeding diathesis
- Significant liver disease, including:; Non-infectious hepatitis; Hepatic cirrhosis (Child-Pugh Class B and Class C)
- Significant pulmonary disease or condition, including:; Significant symptomatic COPD, as assessed by the Investigator; History or any current evidence on imaging studies of interstitial lung disease, pulmonary fibrosis; History of pulmonary inflammatory disease, pneumonitis, ARDS; History of pneumonia within 1 month
- Significant corneal disease or condition, including history of or current evidence of keratitis
- Clinically significant CNS disease or condition including PML, epilepsy, vasculitis, or neurodegenerative disease. Also including TIA or stroke within 6 months
- Known HIV infection or AIDS
- Active hepatitis B virus or hepatitis C virus infection
- Any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks
- Autoimmune disease or condition requiring systemic steroids or other immunosuppressive medications
- Known or suspected hypersensitivity to any of the excipients of formulated study drug
- A psychiatric disorder or altered mental status that would preclude understanding of the informed consent process; Drugs and Other Treatments to be Excluded:
- Any other antineoplastic agent for the primary malignancy without delayed toxicity within 3 weeks or 5 plasma half-lives, whichever is shortest (except nitrosoureas and mitomycin C within 6 weeks)
- Live/live-attenuated vaccines against infectious diseases within 4 weeks
- Any of the following hematologic abnormalities at baseline (transfusion allowed > 5 days previous):; Hemoglobin < 8.0 g/dL; Absolute neutrophil count < 1,000 per mm3; Platelet count < 75,000 per mm3
- Any of the following laboratory abnormalities at baseline:; Total bilirubin > 1.5 × upper limit of normal (ULN); > 3 × ULN if with Gilbert's Syndrome; AST or ALT > 3 × ULN; > 5 × ULN if due to hepatic involvement by tumor; Estimated GFR ≤ 60 mL/min corrected for BSA; Albuminuria defined as urine albumin to creatinine ratio < 30 mg/g or < 3 mg/mmol) by spot urine albumin
- Any of the following coagulation parameter abnormalities at baseline unless on a stable dose of anticoagulant therapy for a prior thrombotic event:; PT or INR > 1.5 × ULN; > 3× ULN if anticoagulated); PTT > 1.5 × ULN; > 3× ULN if anticoagulated
- Any of the following laboratory abnormalities at baseline aimed at assessing renal function:; Estimated glomerular filtration rate (eGFR) ≤ 60 mL/min, corrected for BSA; Albuminuria defined as urine albumin to creatinine ratio (UACR) ≥ 45 mg/g or ≥ 4.5 mg/mmol by spot urine albumin
- Significant cardiovascular disease or condition, including:; Congestive heart failure or angina pectoris requiring therapy; Ventricular arrhythmia requiring therapy or other uncontrolled arrhythmia; Severe conduction disturbance (e.g., 3rd degree heart block); QTc interval ≥ 480 milliseconds; Left ventricular ejection fraction below the lower limit of normal or < 50% by MUGA scan or echocardiogram; Class III or IV cardiovascular disease according to the New York Heart Association Functional Classification; History of acute coronary syndromes (e.g., MI, unstable angina), coronary angioplasty, stenting, or bypass within 6 months
- Unresolved Grade > 1 AE associated with any prior antineoplastic therapy (except persistent Grade 2 alopecia, peripheral neuropathy, decreased hemoglobin, neutropenia, lymphopenia, hypomagnesemia, and/or endocrine end-organ failure being adequately managed by HRT)
- Any other serious, life-threatening, or unstable preexisting medical condition, including significant organ system dysfunction, or clinically significant laboratory abnormality(ies)
- Patients documented to be CD19-negative
- Any other investigational treatments within 3 weeks
- Prophylactic use of hematopoietic growth factors within 1 week
Where in United States
Also in 4 other countries, 12 sites
- University of Maryland, BaltimoreBaltimore, United StatesContact: David BrowningNo longer taking part
About the trial
What the trial wants to find out
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).
The 5 groups in the trial
- Dose Escalation Cohort (Part 1)Treatment being tested
Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Treatment: IKS03
- Dose Expansion: Diffuse-Large B-Cell Lymphoma ParticipantsTreatment being tested
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Treatment: IKS03
- Dose Expansion: Follicular Cell Lymphoma ParticipantsTreatment being tested
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Treatment: IKS03
- Dose Expansion: Mantle Cell Lymphoma ParticipantsTreatment being tested
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Treatment: IKS03
- Dose Expansion: Other B cell lymphoma (B-NHL not otherwise specified [NOS])Treatment being tested
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Treatment: IKS03
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas (NHL)
- Plain-language title
- Tests IKS03 drug in adults with advanced B-cell non-Hodgkin lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 November 2026